Rheumatology
Conference Coverage
Link between knee pain, sleep disturbance related to daily activities
Findings suggested that it’s only knee pain, not the severity of knee osteoarthritis, that’s significantly associated with sleep disturbances, and...
From the Journals
Psoriatic arthritis treatment for women falls short, study suggests
Women with psoriatic arthritis who were treated with ustekinumab or a tumor necrosis factor inhibitor had lower response rates and persistence at...
Conference Coverage
Presurgical expectations may influence patients’ attitudes, experiences after knee replacement
It may be worthwhile to discuss patients’ expectations about what they will be able to do with their knees postoperatively, but it’s unclear...
Latest News
Novel therapy shows promise for treating skin-predominant dermatomyositis
The study drug “is a potent, selective humanized IgG1-neutralizing antibody directed at IFN-beta,” said Dr. Aaron Mangold, the principal...
Conference Coverage
Early exercise intervention improves knee osteoarthritis
Even patients whose symptoms have lasted less than a year experience improvements in pain and physical function when they initiate exercise...
From the Journals
Holy smoke: Air pollution link to bone damage confirmed
‘The scientific literature ... is clearly pointing toward a negative effect of chronic pollution exposure on bone health,’ says expert. New study...
Guidelines
Guidelines: Don’t delay total joint arthroplasty for additional nonoperative therapies
The guidelines also state that obesity alone should not be a reason to delay surgery.
Latest News
JAK inhibitor safety warnings drawn from rheumatologic data may be misleading in dermatology
The recently approved deucravacitinib is the only JAK inhibitor that has so far been exempt from these warnings.
From the Journals
Biologics show signs of delaying arthritis in psoriasis patients
Treatment with the interleukin-12/23 inhibitor ustekinumab or interleukin-23 inhibitors (guselkumab, risankizumab, tildrakizumab) was linked to a...
News from the FDA/CDC
FDA approves first biologic treatment for polymyalgia rheumatica
The interleukin-6 receptor antagonist sarilumab (Kevzara) will be indicated in adults who have had an inadequate response to corticosteroids or...
From the Journals
Isolated nail psoriasis may bring arthritis into play
The review of 20 years of cases show delayed diagnosis, delineate clinical features, and suggest a relationship with PsA.